Future of Merck

Quote

Anonymous

Guest
The Foolish bottom line
In closing, Merck is not a lost cause yet. Although the company has been hit hard by the double whammy of generic competition and pipeline failures, its drastic workforce reductions and restructuring efforts should help it maintain its top and bottom line balance for now.

Looking forward, investors should pay close attention to Merck's pipeline to see if Roger Perlmutter's restructuring efforts are paying off. If Merck can rectify its R&D problems and make progress in its oncology and diabetes treatments, it might be able to get on the right track over the next two years.
 








Anonymous said:
The Foolish bottom line
In closing, Merck is not a lost cause yet. Although the company has been hit hard by the double whammy of generic competition and pipeline failures, its drastic workforce reductions and restructuring efforts should help it maintain its top and bottom line balance for now.

Looking forward, investors should pay close attention to Merck's pipeline to see if Roger Perlmutter's restructuring efforts are paying off. If Merck can rectify its R&D problems and make progress in its oncology and diabetes treatments, it might be able to get on the right track over the next two years.
Click to expand...

Are you preaching patience because all will be right. For eight years we have heard that salvation is just around the corner. Besides balancing the numbers to ensure the future of the shareholders what exactly to you expect to see that indicates that we are on the "right track"? Seriously, what does pipeline improvement look like, so I can recognize it when I see it.
 




Top Bottom
Back
Quote